Vickers Vantage Corp. I (NASDAQ: VCKA) announced this afternoon that its shareholders have approved its combination with commercial biopharmaceutical company Scilex, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), at a special meeting held yesterday, November 9.
At the meeting, holders of 10,198,275 shares were present by proxy or in person, representing 77.398% of the total Vickers ordinary shares outstanding. The business combination was approved with 8,202,588 votes in favor of it, and 1,781,233 votes against the proposal.
The press release did not divulge redemption figures, but VCKA traded below its trust value of $10.10 throughout its redemption deadline on November 7. VCKA opened today at $9.03, but has dropped 15% to $8.50, while SRNE has climbed approximately 15% on the announcement to $1.62.
Nonetheless, shares of the common stock will trade on the Nasdaq Capital Market on Friday, November 11, under the ticker symbol “SCLX”.
Vickers Vantage I originally announced its $1.64 billion combination with Scilex on March 18, 2022. The Palo Alto-based company focuses on the development and commercialization of non-opioid pain management products for treatment of acute and chronic pain.
ADVISORS
- Loeb & Loeb, LLP is serving as legal counsel to VCKA.
- Paul Hastings LLP is serving as legal counsel to Scilex.
Remember the metaverse? Many do not. Meta’s (NASDAQ:META) attempted transition to virtually living and working seemed to mark a trend that went up and down quickly, but one SPAC deal has both survived that roller coaster and may rise with a second. Back in December 2022, Newbury Street (NASDAQ:NBST) announced a $1.85 billion combination with...
At the SPAC of Dawn Tucked into the bill that provides $95 billion in funding to American allies passed by the House this weekend is another measure that is likely to have far more impact on at least one pending deal in SPAC world. It would appear that the timing was fortuitous for TikTok rival...
With the passage this weekend of $95 billion in funding for Ukraine, Israel and Taiwan by the House of Representatives, some focus has gone back towards the defense sector, which has generally had a good year as a whole. But, SPACs have not been as active in defense, despite the fact that companies in the...
At the SPAC of Dawn As April’s sleepy month for SPAC news continues, there is only one special meeting on the docket to consider a SPAC deal approval, that being today’s vote on Pegasus Digital Mobility‘s (NYSE:PGSS) combination with equipment manufacturer Schmid. Three more SPACs are facing extension votes this week, including Pyrophyte (NYSE:PHYT), whose...
Terms Tracker for the Week Ending April 19, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Passover and school spring break starts next week, which most likely means a slowdown in SPAC filing activity. Although Churchill IX is now rumored to...